The trouble with making combination drugs | PDF (93 KB)

p881 | doi:10.1038/nrd2188

Study reveals secrets to faster drug development | PDF (107 KB)

p883 | doi:10.1038/nrd2189

Drug metabolism: Enigmatic enzyme | PDF (123 KB)

p893 | doi:10.1038/nrd2183

Anticancer drugs: Downstream GPCR inhibition | PDF (95 KB)

p894 | doi:10.1038/nrd2181

Infectious disease: Boosting genetic vaccination | PDF (72 KB)

p894 | doi:10.1038/nrd2184

Chemical genomics: Joining the small-molecule dots | PDF (83 KB)

p895 | doi:10.1038/nrd2182

Inflammation: Helping hand for halting inflammation | PDF (77 KB)

p896 | doi:10.1038/nrd2185

PI3K inhibition: towards an 'aspirin of the 21st century'?

Thomas Rückle, Matthias K. Schwarz & Christian Rommel

p903 | doi:10.1038/nrd2145

Phosphatidylinositol 3-kinase (PI3K) is an emerging target for the development of drugs with anti-inflammatory and/or cardioprotective activity. Rommel and colleagues review the biology of this key signalling molecule and discuss current efforts to develop selective PI3K inhibitors.

• Abstract
• Full Text
• PDF (1,437 KB)

The obesity pipeline: current strategies in the development of anti-obesity drugs

Dunstan Cooke & Steve Bloom

p919 | doi:10.1038/nrd2136

The potential market for obesity drugs is huge, and current therapies are limited by their side effects and modest efficacy. Cooke and Bloom provide insights into current anti-obesity strategies, with a focus gut peptides as a promising source for future obesity therapies.

• Abstract
• Full Text
• PDF (939 KB)

Issues in the design and implementation of vaccine trials in less developed countries

Jacqueline L. Deen & John D. Clemens

p932 | doi:10.1038/nrd2159

The global infectious disease burden primarily falls on the developing world. Deen and Clemens discuss several issues in the design and implementation of vaccine trials in less developed countries, as well as ethical issues arising from such trials.

• Abstract
• Full Text
• PDF (338 KB)

Innovative lead discovery strategies for tropical diseases

Solomon Nwaka & Alan Hudson

p941 | doi:10.1038/nrd2144

Lead discovery is a major bottleneck in the pipeline for novel drugs for tropical diseases such as malaria. Nwaka and Hudson discuss how lead-discovery strategies based on highly integrated partnerships and networks involving academia and industry in industrialized and disease-endemic countries could increase the chances of success.

• Abstract
• Full Text
• PDF (333 KB)

Model organisms: Drug discovery in dementia: the role of rodent models

Debby Van Dam & Peter Paul De Deyn

p956 | doi:10.1038/nrd2075

Animal models contribute to advancing our understanding of the pathophysiology of complex disorders and the preclinical assessment of therapeutics for these diseases. Van Dam and De Deyn review the major rodent models of Alzheimer's disease and evaluate their usefulness for drug discovery research

• Abstract
• Full Text
• PDF (463 KB)

Career snapshots: Making the right move

p971 | doi:10.1038/nrd2187

• Abstract
• Full Text
• PDF (69 KB)